Beaujon Hospital

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH

Retrieved on: 
Wednesday, September 7, 2022
Beaujon Hospital, Partnership, Vascular disease, Paris Diderot University, CEO, National Institute, Imaging, SIB, Artificial intelligence, Liver, INSERM, Trial of the century, CEA, Seminal vesicles, Pathology, Artificiality, Digital pathology, Commissariat, Physics, Swiss Institute of Bioinformatics, Fatty liver disease, Diagnosis, Diabetes, Medical research, Inflammation, Type 2 diabetes, Fibrosis, GLOBE, Biostatistics, Leadership, Princeton University, NASH, University, Assistance, Data, Patient, QUID, Medical imaging, T2D, Beaujon

The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.

Key Points: 
  • The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
  • This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D patients.
  • Its multivendor platform, FibroNest, is delivered worldwide via the cloud and used in multiple pre-clinical and clinical studies across several fibrotic conditions.
  • For more information about FibroNest and PharmaNest, visit www.pharmanest.com and www.fibronest.com

Mursla Announces Key Appointments to Advisory Board

Retrieved on: 
Wednesday, November 17, 2021
Biotechnology, Finance, Surgery, Health, Professional Services, NTA, Gene, Mortality, University, Cancer, Robotics, Biomarker, Budd–Chiari syndrome, COO, Therapy, Bachelor of Engineering, MD, ISEV, Engineering, International Society, ISCT, International Society for Extracellular Vesicles, IFCM, Coronavirus Scientific Advisory Board (Turkey), CEO, Doctor of Philosophy, Exosome, Portal vein thrombosis, Beaujon Hospital, Automation, Liver cancer, Fluid mechanics, University of Duisburg-Essen, Helmy Eltoukhy, Research, Inflammation, AI, Seminal vesicles, Liquid biopsy, Institute of Liver and Biliary Sciences, Hepatocellular carcinoma, Culture, EV, Biotechnology, Synthetic biology, Publication, Diagnosis, Advisory board, Review, Cell, HCC, DNA, DNA sequencing, Patient, Risk, Myriad Genetics, Pharmaceutical industry, Vaccine, Medical imaging

Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.

Key Points: 
  • Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
  • He used to sit on the scientific advisory board of EVOX Therapeutics.
  • Mursla is a Cambridge-based liquid biopsy company based on a novel tech platform, ExoPheno, which traces diseases in biofluids via exosomes.
  • Using nanoelectronics and bioengineering, Mursla is developing its platform to detect dozens of cancer types with a single blood test, starting with liver cancer surveillance.

ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer

Retrieved on: 
Monday, October 25, 2021
Disease, ISIN, CI, BLA, Nasdaq, Webcast, CAC Mid 60, COVID-19, 150, Gemcitabine, Doctor of Philosophy, Survival, Food, ALL, CAC All-Tradable, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acute lymphoblastic leukemia, Company, EDT, Conference call, IST, Organic acid, Asparaginase, Pancreatic cancer, CEST, Asparagine, OS, Hypersensitivity, GMP, Beaujon Hospital, Medicine, Hospital, CEO, Growth, Metabolism, Q&A, Population, CMO, Patient, MD, Technology, Cancer, FDA, CAC, Conference, Intention, Progression-free survival, Pharmaceutical industry, Medical imaging, Property management

Key secondary endpoints of the trial, including progression-free survival, disease control rate and objective response rate, showed benefit in favor of eryaspase.

Key Points: 
  • Key secondary endpoints of the trial, including progression-free survival, disease control rate and objective response rate, showed benefit in favor of eryaspase.
  • Pancreatic cancer is a very challenging, heterogeneous disease, and the results of the TRYbeCA-1 Phase 3 trial have now also encountered this significant hurdle.
  • It is very disappointing that the clinical benefit eryaspase demonstrated in the Phase 2 trial was not confirmed; however, the study has addressed important questions in the management of pancreatic cancer patients.
  • The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer.